Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2005-003891-39Phase 2Terminated
Phase 2, single-arm trial of lenalidomide in multiple myeloma (MM), sponsored by HOVON. Primary endpoint: Progression Free Survival. Started Feb 2007; status: terminated.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on 2005-003891-39.